Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
EBITDA improved by 37% to Rs 338.9 crore in Q1 FY27 from Rs 246.7 crore in Q1 FY27. EBITDA margin for June 2026 quarter was 22.9%, up 256 basis points YoY.
Profit before tax in Q1 FY27 stood at Rs 240.4 crore, up by 66.4% from Rs 144.5 in Q1 FY26.
Dr. Krishna Prasad Chigurupati, chairman & managing director of Granules India, said: 'Our focus remains firmly on regulatory and quality excellence, portfolio transformation toward complex and differentiated products, geographic and customer diversification and scaling new growth engines.
While external cost pressures and supply chain volatility require continuous management for next couple of quarters, we are continuing to invest in R&D largely towards Complex Gx, digitalization, operational excellence, sustainability and talent to support long-term value creation.'
Granules India is a vertically integrated fast growing Indian pharmaceutical company. The company manufactures active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs) and peptides CDMO. It has a global presence extending to over 80 countries with offices across India, US, and UK.
The scrip shed 0.55% to end at Rs 871.10 on the BSE today.
Powered by Capital Market - Live News